

## Exploring the New Horizons in Clinical Research & Development

Gery Rifano

Professor, Diponegoro University, Indonesia, E-mail: geryrifano@gmail.com

We are delighted to welcome you to the prestigious “15th Global Biomarkers and Clinical Research Summit”.


[Biomarkers 2020](#) brings together experts from all aspects to meet and discuss the future of Biomarkers importance in today's world to thrive and survive with better health. The conference is scheduled in the month of **September 17-18, 2020** at **Vienna, Austria** which includes prompt keynote presentations, oral talks, poster presentations and exhibitions. We are optimistic that you will appreciate this upcoming Conference's Scientific Program.

### Market Report

#### Industry Insights:

The international market of biomarkers was valued at around 40 billion USD in 2018 and is expected to increase by a CAGR of 13.7% by 2026. The major share of [biomarkers](#) is due to the advancements in biomarker based diagnostics. The market of biomarkers is growing at an alarming rate due to the increase in the international diseases such as cancer, diabetes and cardiovascular diseases which are mainly caused due to the lifestyle changes like unhealthy diet, unhealthy lifestyle, lack of exercise, and rest. The World Health Organization mentioned that these diseases contribute to around 50% of the total number of deaths annually.

U.S. biomarkers market size, by application, 2014 - 2026, (USD Billion)



Due to the advancements in technology, it is now possible to combine biomarkers with oral drugs to improve the accuracy of treatment. Biomarkers are also used to treat brain disorders and diseases by measuring the brain health over a period of time. Due to the recent advancements in biomarker treatments, the brain diseases can be treated with ease which results in cost cutting and early diagnosis of the patient.

The government is also proving a helping hand by providing initiatives to the patients and cutting the price of healthcare. It is also providing help by shifting their focus on early detection techniques and early cure of disease.

#### Type Insights

**Safety Biomarkers:** Biomarkers are increasingly being adopted by drug discovery and development fields due to its nature. The type of biomarkers known as [safety biomarkers](#) are used in preclinical trials as it reduces the time and cost of development.


**Validation Biomarkers:** These types of biomarkers are expected to exhibit higher growth over the years due to their excessive use in the pharmaceutical industries. These biomarkers are mainly used to predict the failure of drug release depending on the biomarkers with low profile and the patient profile.

**Application Insights:** The largest market share according to the 2018 census is acquired by the drug discovery section and is further expected to hold its place until 2026. Biomarkers play a major role in the impact of future development. The pharma industry is also undertaking extensive research and development in the field of development. As goes with the other pharma industry, [personalized medicine](#) is expected to witness a higher growth and is expected to reach higher demand.

**Disease Insights:** During 2018, the cancer section led the biomarker market, followed by cardiovascular diseases and [neurological diseases](#). This shows that there is a

growing demand for cancer cure diagnostic requirements. The future market is expected to grow in the personalized medicine and strategic medicine field.

Due to the increasing routine healthcare checks and the growing base of the geriatric population, which is at high risk of developing various diseases, the security biomarkers segment held the largest share in 2015. The field of validation biomarkers is one of the fastest growing markets. The increasing R&D initiatives for the development of more specific biomarkers, and hence the subsequent development of companion diagnostics with enhanced accuracy and sensitivity for the effective detection of Important factors contributing to the above-mentioned growth are diseases.



As mentioned earlier the cardiovascular disease segment is seeing a further growth due to poor diet and exercise choices.

Based on the type of biomarker, the market for cancer biomarkers is divided into genetic biomarkers, protein biomarkers and other biomarkers (biomarkers for cells, viruses and carbohydrates). During the forecast period, the segment of genetic biomarkers is expected to rise at the highest CAGR due mainly to developments in high-throughput technologies, such as next-generation sequencing, which have increased the speed and accuracy of the discovery and diagnosis of genetic biomarkers.


**Regional Insights:** Due to the government initiatives, North America is contributing more than 40% of the market share in America. The drug development industries are also expected to grow in the near future due to the increased demand. In Asia the growth is expected to reach a CAGR of 16% due to the leading biomarker companies which are investing in the now developing countries as the cost of trial and development is also very less compared to the already developed countries.

private and public sectors.

- Biomarkers Market by Type: Safety, Efficacy, Validation, Biomarkers
- Market by Application: Diagnostics, Drug discovery & development, Personalized medicines, Others

Biomarkers for diagnosis are divided into two major types, including exposure biomarkers and disease biomarkers. Exposure biomarkers are an emerging technology to identify the individual body's hazardous chemical level. Such biomarkers make it possible to measure the pre-disease condition by diagnosing irregular behaviors. Disease biomarkers are used to identify the condition of the disease and also help validate novel drug clinical trials.

At a CAGR of 13.58 percent between 2015 and 2020, the global biomarkers market is expected to reach \$45.55 trillion from \$24.10 trillion in 2015 by 2020. It is expected that the market will be driven by increased spending on health care & R&D and the increasing usefulness of biomarkers for diagnosis. The low cost of clinical trials in developing countries and new initiatives for biomarker research will also support market growth. On the other hand, the need for high investment in capital, low benefit-cost ratio, poorly suited regulatory & reimbursement systems and high cost of testing and sample collection & storage are the major factors that limit the growth of this market.



Use biomarkers are a key component of market research and assessment. It is the basis on which Healthy Longevity calculation and P4 (Precision, Preventive, Personalized, Participatory) Medicine and Longevity therapy efficacy are based. The study was structured as an in-depth review of the state of the art in biological age biomarkers to efficiently inform stakeholders in the



# Journal of Molecular Biomarkers & Diagnosis

Rifano, J Mol Biomark Diagn 2019, 10:6  
ISSN: 2155-9929

**Contact:**

**Maria Jose | Event Manager**

Biochemistry Conferences

Conference Series LLC

Email: [clinicalresearch@meetingsinfo.org](mailto:clinicalresearch@meetingsinfo.org)

Whatsapp: +44 122 563 7058